SNGX - Soligenix Total Debt to Capital
The Soligenix, Inc. (SNGX) price chart demonstrates a total debt-to-equity ratio of 0.05. Management, led by Christopher Shafer, focuses on the long-term needs of patients and investors. Soligenix, Inc. (SNGX) minimizes risks through government contracts and a broad drug portfolio. Business security is ensured by FDA orphan drug designations and contracts for the development of biodefense vaccines.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_SNGX_-_Soligenix-Inc._-_All-Debt-to-Shareholders-Equity-Ratio "SNGX (Soligenix) Total Debt to Capital history from 07/04/2022 to 10/29/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Soligenix, Inc.
The financing structure is critical for Soligenix, Inc. (SNGX), as the company faces FDA regulatory risks and a chronic liquidity shortage. An analysis of the debt-to-equity ratio allows for an assessment of the proportion of external liabilities relative to total asset value, determining the business's dependence on creditors and the resilience of equity in the face of potential new share offerings to cover losses.